Berkshire Hathaway Names Greg Abel CEO and Completes $9.7B OxyChem Acquisition
Berkshire Hathaway appointed Greg Abel CEO effective January 1, 2026, entrusting him with deployment of its $350 billion cash pile and making his capital-allocation track record critical to returns. The company finalized its $9.7 billion acquisition of OxyChem, expanding North American chemical operations and deploying its cash reserves.
1. Leadership Handover and Governance
On January 1, 2026, Berkshire Hathaway’s board formally elevated Greg Abel to chief executive officer, ending Warren Buffett’s 60-year tenure in that role. Buffett will remain as chairman and retains significant voting control, but Abel now holds final authority over all capital allocation and acquisition decisions. At the company’s 2024 annual meeting, Buffett told shareholders, “I would leave the capital allocation to Greg. He understands businesses extremely well, and if you understand businesses, you understand common stocks.” This endorsement underscores a deliberate succession plan aimed at preserving Berkshire’s decentralized operating model while placing long-term stewardship squarely in Abel’s hands.
2. Stakes Raised by Massive Cash Hoard
Berkshire enters the Abel era with more than $350 billion in cash, cash equivalents and short-term Treasuries on its balance sheet. That level of liquidity is unprecedented among major conglomerates and means that even a single transaction involving tens of billions of dollars could meaningfully shift shareholder returns. Abel inherits responsibility for deploying funds across acquisitions, share repurchases and public-equity investments. With Todd Combs’s recent departure, questions swirl over how much of the public-stock portfolio will be managed by Ted Weschler versus allocated directly by Abel, who Buffett has identified as his preferred steward.
3. Early Signals for Market Participants
Investors will watch closely for Berkshire’s first substantial capital move under Abel’s leadership. A bolt-on acquisition or equity purchase of less than $1 billion is unlikely to offer clear insight—only a transaction measured in tens of billions will reveal his strategic priorities. Equally telling will be any resumption of share buybacks: since the second quarter of 2024, Berkshire has not repurchased common stock. A recommencement of repurchases in early 2025 would signal Abel’s conviction that the shares are undervalued, while continued restraint would reinforce the company’s hallmark discipline and patience.